Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 2
1958 1
1959 2
1962 2
1973 1
1974 1
1975 2
1976 4
1977 2
1978 2
1979 1
1980 1
1981 2
1982 2
2004 1
2005 3
2006 2
2007 4
2008 2
2010 2
2011 5
2012 4
2013 3
2014 5
2015 4
2016 4
2017 3
2018 5
2019 3
2020 1
2021 3
2022 2
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Transition of care.
Spahr J, Hayes D Jr. Spahr J, et al. Virtual Mentor. 2005 Mar 1;7(3):virtualmentor.2005.7.3.ccas3-0503. doi: 10.1001/virtualmentor.2005.7.3.ccas3-0503. Virtual Mentor. 2005. PMID: 23249488 Free article. No abstract available.
Priority Considerations for Medicinal Cannabis-Related Research.
Bonn-Miller MO, Pollack CV Jr, Casarett D, Dart R, ElSohly M, Good L, Guzmán M, Hanuš L, Hill KP, Huestis MA, Marsh E, Sisley S, Skinner N, Spahr J, Vandrey R, Viscusi E, Ware MA, Abrams D. Bonn-Miller MO, et al. Among authors: spahr j. Cannabis Cannabinoid Res. 2019 Sep 23;4(3):139-157. doi: 10.1089/can.2019.0045. eCollection 2019. Cannabis Cannabinoid Res. 2019. PMID: 31579832 Free PMC article. No abstract available.
[Proteinuria].
Fabre J, Balant L, Spahr J. Fabre J, et al. Among authors: spahr j. Rev Med Suisse Romande. 1978 Nov;98(11):583-8. Rev Med Suisse Romande. 1978. PMID: 734274 French. No abstract available.
Static perimetry: strategies.
Bebie H, Fankhauser F, Spahr J. Bebie H, et al. Among authors: spahr j. Acta Ophthalmol (Copenh). 1976 Jul;54(3):325-38. doi: 10.1111/j.1755-3768.1976.tb01262.x. Acta Ophthalmol (Copenh). 1976. PMID: 988949
74 results